TherapeuticsMD, Inc. (TXMD)
| Market Cap | 413.68M |
| Revenue (ttm) | 58.20M |
| Net Income (ttm) | -190.87M |
| Shares Out | 272.56M |
| EPS (ttm) | -0.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $1.38 |
| Previous Close | $1.44 |
| Change ($) | -0.06 |
| Change (%) | -4.17% |
| Day's Open | 1.43 |
| Day's Range | 1.38 - 1.46 |
| Day's Volume | 5,286,629 |
| 52-Week Range | 0.87 - 2.81 |
TherapeuticsMD (TXMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD to present at H.C. Wainwright BioConnect Conference and J.P. Morgan Virtual HealthCare Conference in January 2021
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD closes offering; sold 23,437,500 shares of its common stock for net proceeds of approximately $27.5 million
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD to present at Stifel 2020 Virtual Healthcare Conference on Tuesday, Nov. 17 at 9:20 a.m. ET; see details for live webcast
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 23.4 million shares of its common stock f...
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced an underwritten public offering of its common stock. The Company has granted the underwriter a 30-day opti...
TherapeuticsMD's (TXMD) CEO Robert Finizio on Q3 2020 Results - Earnings Call Transcript
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 28.57% and 9.47%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of TherapeuticsMD (NASDAQ:TXMD) moved higher by 2.5% in pre-market trading after the company reported Q3 results.
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD releases Q3 business and financial results; holds conference call at 8:30 am ET today
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD to hold conference call to discuss Q3 financial and business results on Monday, November 9 at 8:30 am ET
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Give TXMD stock a try if you're ready to expand your portfolio's horizons with a stake in innovative women's health care products. The post Delve into an Underappreciated Health Care Niche wit...
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, is proud to reinforce the importance of empowering women to make informed choic...
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
BOCA RATON, Fla.--(BUSINESS WIRE)--3Q Update PR
MONTREAL and BOCA RATON, Fla., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today th...
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD to participate in two virtual investor conferences in September
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD increases patent protection on ANNOVERA
TherapeuticsMD has been a blemish on my speculative biotech/pharma portfolio for over a year. I went against my rules for trading a premium-priced bio and paid for it.
MONTREAL and BOCA RATON, Fla, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the ...
TherapeuticsMD, Inc. (TXMD) CEO Robert Finizio on Q2 2020 Results - Earnings Call Transcript
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -13.33% and -10.30%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD discusses business and financial results for Q2 2020 on earnings conference call today at 8:30 a.m.
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc.
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOCA RATON, Fla. & SAN FRANCISCO--(BUSINESS WIRE)--TXMD expands access to Annovera through arrangement with Nurx, the largest online practice for women's health
Being concerned about the elevated levels of the market is likely to be on many investors’ minds ahead of a slew of corporate earnings coming, not to mention an election season that is only go...
Have extra cash to spare? These drug stocks are significantly undervalued and could make you wealthy in the long run.
TherapeuticsMD, Inc. (TXMD) CEO Robert Finizio on Q1 2020 Results - Earnings Call Transcript
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -10.53% and 6.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
A newly issued patent could provide market exclusivity for its long-term contraceptive device.
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
TherapeuticsMD Reports Encouraging Q4/2019 Earnings But The Market Doesn't Care
TherapeuticsMD, Inc. (TXMD) CEO Robert Finizio on Q4 2019 Results - Earnings Call Transcript
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 5.00% and 20.33%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The company already has three women's healthcare products available on the market.
Shares pop after an SEC filing reveals that the biopharma has attracted the attention of a major financial institution.
TherapeuticsMD's Business Model Affirms Additional Dilution Is Practically Certain In FY2020
TherapeuticsMD: Hits Upper-End Of Q3 Guidance And Establishes Momentum Into 2020
TherapeuticsMD, Inc. (TXMD) CEO Robert Finizio on Q3 2019 Results - Earnings Call Transcript
TherapeuticsMD (TXMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors are bracing for dilution from a proposed share offering.
The path ahead is looking a bit brighter for this pharmaceutical company.
August sales figures suggest the company's strategy is working.
About TXMD
TherapeuticsMD operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-00THR and TX-0008HR... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | |
| CEO Robert Finizio | Employees 348 |
| Stock Exchange NASDAQ | Ticker Symbol TXMD |
Financial Performance
In 2019, TherapeuticsMD's revenue was $49.65 million, an increase of 208.38% compared to the previous year's $16.10 million. Losses were -$176.14 million, 32.8% more than in 2018.
Analyst Forecasts
According to 7 analysts, the average rating for TherapeuticsMD stock is "Strong Buy." The 12-month stock price forecast is 6.43, which is an increase of 365.94% from the latest price.